Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid Cancer.
Selpercatinib在晚期<i>RET</i>突變髓質甲狀腺癌的第3期試驗。
N Engl J Med 2024-02-28
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC.
<i>RET</i>融合陽性非小細胞肺癌的一線治療:Selpercatinib或化療和Pembrolizumab。
N Engl J Med 2024-03-30
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Zibotentan與dapagliflozin組合藥物與單獨dapagliflozin在慢性腎臟病患者中的比較(ZENITH-CKD):一項多中心、隨機、主動對照、2b期臨床試驗。
Lancet 2023-12-12
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
Tivozanib 加 nivolumab 與 tivozanib 單藥治療在接受免疫檢查點抑制劑後的腎細胞癌患者中的比較:第 3 期 TiNivo-2 研究結果。
Lancet 2024-09-16